The global lung cancer therapeutics market is projected at a valuation of USD 37.5 billion in 2024. The revenue is likely to escalate to USD 112.8 billion in 2034 driven by the evolution of targeted medicine. The lung cancer therapeutics market is estimated to register a CAGR of 11.7% between 2024 and 2034
Global Lung Cancer Therapeutics Market Assessment
| Attributes | Description |
|---|---|
| Estimated Global Lung Cancer Therapeutics Market Size (2024E) | USD 37.5 billion |
| Projected Global Lung Cancer Therapeutics Market Value (2034F) | USD 112.8 billion |
| Value-based CAGR (2024 to 2034) | 11.7% |
Precision medicine focuses on tailoring therapies based on the genetic and molecular characteristics of tumors. In Nonsmall Cell Lung Cancer (NSCLC), specific genetic mutations such as EGFR, ALK, ROS1, and BRAF play critical roles in tumor development. By targeting these mutations, cell and gene therapies can provide more effective treatment options, improving outcomes for patients with complex cancer profiles.
The increasing accessibility and affordability of genomic testing are driving the adoption of precision medicine in lung cancer. Previously, broad-spectrum treatments were the norm, often leading to suboptimal results. Now, genomic testing allows for a deeper understanding of each patient's cancer, enabling healthcare providers to develop targeted treatment strategies.
Moreover, the lung cancer therapeutics market is expanding with increased accessibility and affordability of genomic testing and precision medicine. The rise in the use of precision medicine, in which, genomic testing is the driving force has resulted in better treatment approaches toward the patients and thus leads to market growth.
On the other hand, the market is responding to the demand for new drugs with more combination therapies that address ‘treatment’ resistance, which is an enhancement of existing therapies. Nonetheless, territories are being encroached faster than expected. Hence, pharmaceutical firms are turning to forming joint ventures and alliances to gain a competitive edge.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The lung cancer therapeutics market shows promising growth potential. From 2024 to 2034, the market is slated to grow variably. The first half of 2023 to 2033 expects a CAGR of 12.6%. The second half of this period projects a CAGR of 12.1%. This slight decrease indicates a steady fall in demand.
| Particular | Value CAGR |
|---|---|
| H1 | 12.6% (2023 to 2033) |
| H2 | 12.1% (2023 to 2033) |
| H1 | 11.7% (2024 to 2034) |
| H2 | 11.2% (2024 to 2034) |
In the next decade though, the first half maintains a steady CAGR of 11.7%. The second half of 2024 to 2034, however, sees a growth at a CAGR of 11.2%.
Demand for Combination Therapies for Lung Cancer Treatment is on the Rise
New combination therapies in immuno-oncology are expanding treatment options for lung cancer. These therapies are especially beneficial for patients with advanced or metastatic disease. By combining immune checkpoint inhibitors with chemotherapy, radiotherapy, or targeted agents, more patients can access effective treatments. This approach may help those whose cancers did not respond to immunotherapies alone.
Rising Number of Smokers to Necessitate the Demand for Lung Cancer Therapeutics
The rising smoking rates in low- and middle-income countries (LMICs) present significant opportunities for the lung cancer therapeutics market. In France, there are approximately 16.4 million tobacco users, ranking it third in the WHO European Region.
While smoking rates are declining in high-income countries like America, Japan, and France, LMICs continue to see an increase. As smoking prevalence rises, more lung cancer cases are expected, driving demand for both traditional chemotherapy and advanced immuno-oncology therapies.
Restraints in the Lung Cancer Therapeutics Market
Despite advancements in treatment options like targeted therapies and immunotherapy, early-stage diagnosis remains crucial. The lack of extensive screening programs hampers early detection efforts. Low-dose computed tomography (LDCT) has proven effective in identifying lung cancer at more treatable stages. However, without improved early detection strategies, the effectiveness of therapeutic agent remains constrained.
Principal Consultant
In 2019, the global market for lung cancer therapeutics was valued at USD 25.4 billion. The last decade witnessed a significant transformation in the lung cancer therapeutics market from conventional to more refined and directed methods. The earlier forms of therapy were mainly surgical and radiological interventions supplemented with chemotherapy.
Although most of these approaches were efficacious in certain situations, they were however very much limited in effectiveness, and severe adverse effects were experienced in patients, especially those with advanced stages of lung cancer.
Some of the adverse effects included fatigue, nausea, and respiratory complications. Additionally, treatments could lead to immune-related issues, including pneumonitis and severe allergic reactions, further complicating patient management.
Platinum-based chemotherapy marked a turning point in the treatment of lung cancer. Chemotherapy was the standard therapy a decade back; however, this therapy is generally not sufficient for reasons other than its high toxicity, given the only imitated survival benefit.
With technological advancements and focus on clinical research, healthcare providers have made therapy more effective and cost-efficient. Additionally, access to these therapies and positive outcomes has facilitated the scope of lung cancer therapeutics.
Furthermore, the most track-breaking advancement in lung cancer treatment in the last few years is immunotherapy, and immune checkpoint inhibitors- PD-1/PD-L1 inhibitors. Such treatments have proved their efficiency in several cases, particularly in cases where PD-L1 expression level is high. All these upgrades and launches in the healthcare domain prove the uptrend of these therapies in lung cancer treatment.
Tier 1 pharmaceutical companies like Roche, Bristol-Myers Squibb, and AstraZeneca are rapidly making strategic product launches and collaborations to gain a foothold in the market. For instance, Roche’s Atezolizumab and AstraZeneca’s Osimertinib have demonstrated incredible results in the management of advanced-stage lung malignancy.
Moreover, tier 1 players are also resorting to strategic partnerships and collaborative agreements to use their capabilities in new markets. One such merger has enabled Bristol-Myers Squibb to strengthen its oncology portfolio with the acquisition of Celgene.
Tier 2 companies including Hengrui Medicine, Cipla, and Zymeworks, are gaining ground in the lung cancer therapeutics market and working to increase their market shares. These healthcare providers are also targeting niche markets and providing cheaper substitutes for the therapies that already exist.
Camrelizumab, a novel immunotherapy, was introduced by Hengrui Medicine, highlighting its commitment to addressing unmet needs in lung cancer treatment. In addition, investment in the expansion of tier 2 companies has been through collaborations and partnerships; for instance, Cipla has formed strategic alliances for research focused on drug development.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section summarizes the leading countries expanding in the global lung cancer therapeutics market. The table describes the CAGRs of specific countries and the data highlights key trends, projects, and company contributions to position the country in the global landscape. This data helps investors keenly observe and go through the recent trends and examine them in order.
| Countries | CAGR 2024 to 2034 |
|---|---|
| India | 17.6% |
| China | 17.0% |
| South Korea | 15.4% |
| Germany | 13.2% |
| Australia | 10.4% |
| United States | 6.6% |
Leading players like Dr. Reddy’s Laboratories, Cipla, and Sun Pharmaceutical Industries are engaged in developing and marketing novel treatments and generics for lung cancer. For instance, Dr. Reddy has released its generic version of Erlotinib for non-small cell lung cancer.
At the same time, Cipla has widened its scope with the introduction of Nivolumab, which is also an immunotherapy drug. These players are capitalizing on cheap manufacturing costs in India to meet the treatment needs both in India and abroad.
Moreover, the rising demand for the lung cancer therapeutics market in India is the result of the development of clinical research and healthcare infrastructure. The number of clinical trials in the country has also increased with the help of institutions such as the Indian Council of Medical Research (ICMR) which supports research in the country.
This upsurge in the number of clinical trials is further assisted by technological aspects of the healthcare facilities enabling patients to seek out more advanced treatments.
The lung cancer therapeutics market in China is growing at an unprecedented pace, driven by a large pool of lung cancer patients and an equally strong pharmaceutical industry dedicated to developing innovative treatment options. Major players including Hengrui Medicine, Zhejiang Huahai Pharmaceutical, and Jiangsu Hengrui Medicine have made notable strides by launching targeted therapies and immunotherapies.
For instance, Hengrui launched Sunitinib, an advanced targeted agent for lung cancer, while Jiangsu Hengrui’s Camrelizumab serves as an additional immune therapy. Such launches are much awaited in any country with lung cancer epidemic given the prevalence of smoking and environmental ozone.
In addition, attention was drawn to the importance of conducting cancer research, which explains why there are a lot of studies conducted on new therapies and precision medicine. This growth is reinforced by the National Natural Science Foundation which supports the development of innovative cancer treatments.
The lung cancer therapeutics market in Germany is expanding rapidly due to the flourishing pharmaceutical market and emphasis on research and development.
Additionally, investments by Germany in technological upgrades in lung cancer treatment in precision medicine and biomarker research enable researchers and health providers to develop modern solutions. This subsequently led to the incorporation of deep learning and machine learning in the drug development processes, thereby increasing the scope of finding appropriate treatment options for the disease.
For instance, Boehringer Ingleheim registered Alectinib, a drug for ALK-positive non-small cell lung cancer. Likewise, Roche reported the properties of Atezolizumab, an anticancer drug, developed for lung cancer treatment.
The section describes the leading segment in the lung cancer therapeutics market and their share value.
| Segment | Targeted Therapies(Drug Class) |
|---|---|
| Value Share (2024) | 89.8% |
Targeted therapies have become the most prominent class of drugs due to their ability to destroy cancer cells without affecting normal healthy tissues. This approach of medicine is especially useful for lung cancer therapy where multiple genetic mutations are involved. Treatments aimed at the inhibition of mutation specific molecular targets, such as EGFR inhibitors and ALK inhibitors, have provided better outcomes compared to general therapy.
The effectiveness of targeted therapies lies the personalized treatment strategies. These strategies allow healthcare providers to tailor therapies based on individual patient profiles. This approach, apart from increasing the chances of success in the treatment, also alleviates the adverse effects usually linked to treatment with chemotherapeutics.
As a result, these therapies are advantageous for patient management because their responses can be assessed better and quickly, making it possible to change the treatment as required.
| Segment | Injectable (Formulation) |
|---|---|
| Value Share (2024) | 58.6% |
Some patients believe that injectable forms of medication act rapidly and are effective since they deliver the drug directly into the bloodstream. Such an approach is necessary for the administration of biologics and targeted therapies with narrow therapeutic windows and rapid onset of action. Injectable therapies, for instance, monoclonal antibodies and immunotherapy, are fundamental in the treatment of patients who cannot be expected to tolerate or comply with oral medications.
As for healthcare providers, injectable medications ease the treatment regimens, as there is medication administration control in the clinical setting. This also allows for better observation of the patients during the infusion and for the quick treatment of undesirable effects that may arise.
The lung cancer therapeutics is experiencing intense competition, driven by advancements in targeted therapies. Prominent healthcare providers are making efforts with innovative products and developing cost-efficient solutions. Additionally, companies must focus on strategic collaborations with research to enhance accessibility and maintain a competitive edge in this rapidly evolving landscape.
Industry Updates
The lung cancer therapeutics market includes cytotoxic chemotherapy drugs, targeted therapies, and angiogenesis inhibitors. Cytotoxic chemotherapy drugs are classified as platinum-based chemotherapy, taxanes, antimetabolites, and other chemotherapy agents. Targeted therapies include EGFR inhibitors. tyrosine kinases inhibitors, PD-1 or PD-L1 inhibitors, BRAF inhibitors, KRAS inhibitors, and other targeted therapies. Angiogenesis inhibitors are divided into bevacizumab and ramuciraumab.
The segment is classified into injectable and oral formulations. Injectables are trifurcated into premixed infusion solution for intravenous infusion, sterile solution for intravenous injection, and lyophilized powder for reconstitution for intravenous infusion. Oral formulation is categorized into tablets and capsules.
Small and large molecules are included in this category.
The market is divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Institutional and retail sales are two distribution channels of this segment. Institutional sales are classified into hospitals and specialty centers, cancer research centers, and government and non-government organizations. Retail sales are divided into retail and specialty pharmacies.
Information about the leading countries of North America, Latin America, Western Europe, South Asia and Pacific, East Asia, and the Middle East and Africa is given.
It is anticipated to reach USD 37.5 billion in 2024.
The market is set to rise at a 11.7% CAGR through 2034.
The landscape is forecasted to reach USD 112.8 billion by 2034.
Targeted therapies are the most popular product type with a share value of 89.8%.
AstraZeneca, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc. and Novartis AG are a few key companies.
Explore Healthcare Insights
View Reports
Lung Cancer Therapeutics Market
